Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Assets AverageEnterprise ValueEquity AverageEquity RatioInvested CapitalReturn on AssetsReturn on Capital EmployedReturn on Equity

Aptevo Therapeutics (APVO) Return on Capital Employed (2016 - 2025)

Aptevo Therapeutics' Return on Capital Employed history spans 10 years, with the latest figure at 1.7% for Q3 2025.

  • For Q3 2025, Return on Capital Employed rose 99.0% year-over-year to 1.7%; the TTM value through Sep 2025 reached 1.7%, up 99.0%, while the annual FY2024 figure was 1.76%, 46.0% down from the prior year.
  • Return on Capital Employed for Q3 2025 was 1.7% at Aptevo Therapeutics, up from 3.43% in the prior quarter.
  • Across five years, Return on Capital Employed topped out at 0.63% in Q2 2022 and bottomed at 3.67% in Q1 2025.
  • The 5-year median for Return on Capital Employed is 1.25% (2023), against an average of 1.59%.
  • The largest annual shift saw Return on Capital Employed skyrocketed 143bps in 2021 before it tumbled -178bps in 2025.
  • A 5-year view of Return on Capital Employed shows it stood at 0.84% in 2021, then crashed by -41bps to 1.18% in 2022, then plummeted by -30bps to 1.54% in 2023, then crashed by -74bps to 2.69% in 2024, then soared by 37bps to 1.7% in 2025.
  • Per Business Quant, the three most recent readings for APVO's Return on Capital Employed are 1.7% (Q3 2025), 3.43% (Q2 2025), and 3.67% (Q1 2025).